Other Species / Isoforms
  CAMKK1 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
D24
VERVAAIDVTHLEEA
1 0
CAMKK1 (human) VERVAAIDVTHLEEA D24
CAMKK1 (mouse) VDRVAAINVAHLEEA N24
CAMKK1 (rat) VERVAAIsVAHLEEA S24-p
D32-ca
VTHLEEAdGGPEPTR
0 1
CAMKK1 (human) VTHLEEAdGGPEPTR D32-ca
CAMKK1 (mouse) VAHLEEADEGPEPAR D32
CAMKK1 (rat) VAHLEEAEEGPEPAS E32
S52-p
PPRARAAsVIPGSTS
1 14
CAMKK1 (human) PPRARAAsVIPGSTS S52-p
CAMKK1 (mouse) PPRARAAsVIPGSAS S52-p
CAMKK1 (rat) PPRARAAsVIPGsAs S52-p
S57
AAsVIPGSTSRLLPA
0 1
CAMKK1 (human) AAsVIPGSTSRLLPA S57
CAMKK1 (mouse) AAsVIPGSASRPTPV S57
CAMKK1 (rat) AAsVIPGsAsRPTPV S57-p
S59
sVIPGSTSRLLPARP
0 1
CAMKK1 (human) sVIPGSTSRLLPARP S59
CAMKK1 (mouse) sVIPGSASRPTPVRP S59
CAMKK1 (rat) sVIPGsAsRPTPVRP S59-p
S67-p
RLLPARPsLsARKLs
0 5
CAMKK1 (human) RLLPARPsLsARKLs S67-p
CAMKK1 (mouse) RPTPVRPSLSARKFs S67
CAMKK1 (rat) RPTPVRPSLSARKFs S67
S69-p
LPARPsLsARKLsLQ
0 2
CAMKK1 (human) LPARPsLsARKLsLQ S69-p
CAMKK1 (mouse) TPVRPSLSARKFsLQ S69
CAMKK1 (rat) TPVRPSLSARKFsLQ S69
S74-p
sLsARKLsLQERPAG
Upstream
Downstream
4 26
Effects on Modified Protein
  • enzymatic activity, induced
  • enzymatic activity, inhibited
  • molecular association, regulation
Kinase, in vitro:
  • PKACA (pig)
Putative in vivo kinases:
  • PKACA (human)
CAMKK1 (human) sLsARKLsLQERPAG S74-p
CAMKK1 (mouse) SLSARKFsLQErPAG S74-p
CAMKK1 (rat) SLSARKFsLQERPAG S74-p
R78
RKLsLQERPAGsyLE
0 3
CAMKK1 (human) RKLsLQERPAGsyLE R78
CAMKK1 (mouse) RKFsLQErPAGSCLG R78-m2
CAMKK1 (rat) RKFsLQERPAGSCLE R78
S82-p
LQERPAGsyLEAQAG
0 1
CAMKK1 (human) LQERPAGsyLEAQAG S82-p
CAMKK1 (mouse) LQErPAGSCLGAQVG S82
CAMKK1 (rat) LQERPAGSCLEAQVG S82
Y83-p
QERPAGsyLEAQAGP
0 1
CAMKK1 (human) QERPAGsyLEAQAGP Y83-p
CAMKK1 (mouse) QErPAGSCLGAQVGP C83
CAMKK1 (rat) QERPAGSCLEAQVGP C83
Y91
LEAQAGPYAtGPAsH
0 1
CAMKK1 (human) LEAQAGPYAtGPAsH Y91
CAMKK1 (mouse) LGAQVGPyStGPAsH Y91-p
CAMKK1 (rat) LEAQVGPYSTGPASH Y91
T93-p
AQAGPYAtGPAsHIs
0 2
CAMKK1 (human) AQAGPYAtGPAsHIs T93-p
CAMKK1 (mouse) AQVGPyStGPAsHIs T93-p
CAMKK1 (rat) AQVGPYSTGPASHMS T93
S97-p
PYAtGPAsHIsPrAW
0 2
CAMKK1 (human) PYAtGPAsHIsPrAW S97-p
CAMKK1 (mouse) PyStGPAsHIsPRsW S97-p
CAMKK1 (rat) PYSTGPASHMSPRAW S97
S100-p
tGPAsHIsPrAWRRP
Upstream
0 9
Treatment
  • MG132_withdrawal
CAMKK1 (human) tGPAsHIsPrAWRRP S100-p
CAMKK1 (mouse) tGPAsHIsPRsWRRP S100-p
CAMKK1 (rat) TGPASHMSPRAWRRP S100
R102-m1
PAsHIsPrAWRRPtI
0 1
CAMKK1 (human) PAsHIsPrAWRRPtI R102-m1
CAMKK1 (mouse) PAsHIsPRsWRRPtI R102
CAMKK1 (rat) PASHMSPRAWRRPtI R102
A103
AsHIsPrAWRRPtIE
0 1
CAMKK1 (human) AsHIsPrAWRRPtIE A103
CAMKK1 (mouse) AsHIsPRsWRRPtIE S103-p
CAMKK1 (rat) ASHMSPRAWRRPtIE A103
T108-p
PrAWRRPtIESHHVA
Downstream
7 5
Effects on Modified Protein
  • enzymatic activity, induced
  • enzymatic activity, inhibited
CAMKK1 (human) PrAWRRPtIESHHVA T108-p
CAMKK1 (mouse) PRsWRRPtIESHRVA T108-p
CAMKK1 (rat) PRAWRRPtIESHHVA T108-p
K166
LSKKKLLKQYGFPRR
0 1
CAMKK1 (human) LSKKKLLKQYGFPRR K166
CAMKK1 (mouse) LSKKKLLKQYGFPRR K166
CAMKK1 (rat) LSKKKLLkQYGFPRR K166-ub
K245
VMEVPCDKPFSEEQA
0 1
CAMKK1 (human) VMEVPCDKPFSEEQA K245
CAMKK1 (mouse) VMEVPCDKPFPEEQA K245
CAMKK1 (rat) VMEVPCDkPFPEEQA K245-ub
K277-ub
KIVHRDIkPSNLLLG
0 1
CAMKK1 (human) KIVHRDIkPSNLLLG K277-ub
CAMKK1 (mouse) KIVHRDIKPSNLLLG K277
CAMKK1 (rat) KIVHRDIKPSNLLLG K277
K404
RIGVPDIKLHPWVTK
0 2
CAMKK1 (human) RIGVPDIKLHPWVTK K404
CAMKK1 (mouse) RIGVSDIKLHPWVTK K404
CAMKK1 (rat) RIGVSDIkLHPWVTK K404-ub
S443-p
NSVRLIPsWTtVILV
0 1
CAMKK1 (human) NSVRLIPsWTtVILV S443-p
CAMKK1 (mouse) NSVRLIPSWTTVILV S443
CAMKK1 (rat) NSVKLIPSWTTVILV S443
T446-p
RLIPsWTtVILVKsM
0 1
CAMKK1 (human) RLIPsWTtVILVKsM T446-p
CAMKK1 (mouse) RLIPSWTTVILVKSM T446
CAMKK1 (rat) KLIPSWTTVILVKSM T446
S452-p
TtVILVKsMLRKRsF
0 1
CAMKK1 (human) TtVILVKsMLRKRsF S452-p
CAMKK1 (mouse) TTVILVKSMLRKRsF S452
CAMKK1 (rat) TTVILVKSMLRKRsF S452
S458-p
KsMLRKRsFGNPFEP
Upstream
Downstream
5 46
Effects on Modified Protein
  • enzymatic activity, inhibited
Treatment
  • anti-CD3
  • BI2536
  • nocodazole
CAMKK1 (human) KsMLRKRsFGNPFEP S458-p
CAMKK1 (mouse) KSMLRKRsFGNPFEP S458-p
CAMKK1 (rat) KSMLRKRsFGNPFEP S458-p
R469-m1
PFEPQARrEErsMsA
0 1
CAMKK1 (human) PFEPQARrEErsMsA R469-m1
CAMKK1 (mouse) PFEPQARREERSMsA R469
CAMKK1 (rat) PFEPQARREERSMsA R469
R472-m1
PQARrEErsMsAPGN
0 1
CAMKK1 (human) PQARrEErsMsAPGN R472-m1
CAMKK1 (mouse) PQARREERSMsAPGS R472
CAMKK1 (rat) PQARREERSMsAPGN R472
S473-p
QARrEErsMsAPGNL
0 1
CAMKK1 (human) QARrEErsMsAPGNL S473-p
CAMKK1 (mouse) QARREERSMsAPGSL S473
CAMKK1 (rat) QARREERSMsAPGNL S473
S475-p
RrEErsMsAPGNLLV
Upstream
Downstream
2 21
Effects on Modified Protein
  • enzymatic activity, inhibited
  • molecular association, regulation
Kinase, in vitro:
  • PKACA (pig)
Putative in vivo kinases:
  • PKACA (human)
Treatment
  • ischemia
CAMKK1 (human) RrEErsMsAPGNLLV S475-p
CAMKK1 (mouse) RREERSMsAPGSLLM S475-p
CAMKK1 (rat) RREERSMsAPGNLLL S475-p
S492-p
GFGEGGKsPELPGVQ
0 13
CAMKK1 (human) GFGEGGKsPELPGVQ S492-p
CAMKK1 (mouse) GCGEGCKsPELPGVQ S492-p
CAMKK1 (rat) GCGEGGKSPELPGVQ S492